Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 3/20 | 0.43 |
| ▸ | BCR | P11274 | 3/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SRC | P12931 | 3/20 | 0.41 |
| ▸ | YES1 | P07947 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | ACR | P10323 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4663817 | 0.96 | ABL1 (0.47) | ABL1BCRHRH3MAPTSRC | |
| Formic Acid SCHEMBL4663881 | 0.94 | HRH3 (0.48) | ABL1BCRHRH3MAPTSRC | |
| Formic Acid SCHEMBL4664287 | 0.94 | ABL1 (0.47) | ABL1BCRHRH3MAPT | |
| SCHEMBL4663800 | 0.92 | HRH3 (0.48) | ABL1BCRHRH3MAPTSRC | |
| Formic Acid SCHEMBL4665720 | 0.91 | HRH3 (0.53) | ABL1BCRHRH3MAPT | |
| SCHEMBL4666140 | 0.90 | ABL1 (0.49) | ABL1BCRMAPT | |
| Formic Acid SCHEMBL4665775 | 0.89 | ABL1 (0.48) | ABL1BCRMAPT | |
| Formic Acid SCHEMBL4665644 | 0.89 | ABL1 (0.44) | ABL1BCRMAPTGAA | |
| Formic Acid SCHEMBL4665702 | 0.88 | ABL1 (0.48) | ABL1BCRHRH3MAPT | |
| Formic Acid SCHEMBL4667535 | 0.88 | GSK3B (0.44) | ABL1BCRSRCFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | ALTANA PHARMA AG (DE) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | MAP3K19, MAP3K6, MAP3K20 | ABL1 24/4885BCR 402/4885HRH3 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.